Inspections, Compliance, Enforcement, and Criminal Investigations
Globus Medical Inc. - Close Out Letter 3/18/14
Department of Health and Human Services
|900 U.S. Customhouse|
2nd and Chestnut Streets
Philadelphia, PA 19106
March 18, 2014
RETURN RECEIPT REQUESTED
David C. Paul, President and CEO
Globus Medical Inc.
2560 General Armistead Ave.
Audubon, Pennsylvania, 19403
Dear Mr. Paul:
The Food and Drug Administration (FDA) has completed an evaluation of your firm's corrective actions in response to our Warning Letter 13-PHI-33, dated September 26, 2013. Based on our evaluation, it appears that you have addressed the violation(s) contained in the Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or you firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and it implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Steven L. Carter
Director, Compliance Branch
Philadelphia District Office